Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$130.67 USD

130.67
1,234,708

+2.92 (2.29%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $130.73 +0.06 (0.05%) 6:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.

Zacks Equity Research

Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.

Zacks Equity Research

LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.

Sweta Jaiswal, FRM headshot

Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

Zacks Equity Research

OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.

Zacks Equity Research

Globus Medical (GMED) Misses on Q1 Earnings and Revenues

by Zacks Equity Research

Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises

by Zacks Equity Research

Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.

Zacks Equity Research

Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.

Zacks Equity Research

Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook

by Zacks Equity Research

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Zacks Equity Research

Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

Zacks Equity Research

Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended

by Zacks Equity Research

Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Zacks Equity Research

Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.

Zacks Equity Research

Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls

by Zacks Equity Research

Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.

Zacks Equity Research

NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.

Zacks Equity Research

QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up

by Zacks Equity Research

QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.

Zacks Equity Research

AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.

Zacks Equity Research

Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.

Zacks Equity Research

Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.

Zacks Equity Research

Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

Zacks Equity Research

Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.

Zacks Equity Research

Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View

by Zacks Equity Research

Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.

Zacks Equity Research

CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate

by Zacks Equity Research

Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand

by Zacks Equity Research

Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.